According to a new report from Intel Market Research, the global Cabozantinib Drug market was valued at USD 2.12 billion in 2025 and is projected to reach USD 4.01 billion by 2034, growing at a robust CAGR of 7.5% during the forecast period (2026–2034). This growth is propelled by the escalating global burden of cancer, particularly renal and liver cancers, alongside expanding clinical...

According to a new report from Intel Market Research, the global Pembrolizumab market was valued at USD 21.8 billion in 2025 and is projected to grow from USD 24.3 billion in 2026 to USD 42.7 billion by 2034, exhibiting a robust CAGR of 7.3% during the forecast period. This growth is driven by increasing cancer prevalence, rising immunotherapy adoption, expanding regulatory approvals for new...

The global intravesical Bacillus Calmette market is experiencing significant growth due to the increasing prevalence of bladder cancer and the rising adoption of immunotherapy-based treatment approaches. Intravesical Bacillus Calmette therapy has become one of the most widely used treatment options for non-muscle invasive bladder cancer (NMIBC), offering effective recurrence prevention and...

The global oncology therapeutics industry is experiencing rapid advancement due to the increasing prevalence of cancer and the growing adoption of immunotherapy-based treatments. Tecentriq, an immunotherapy drug widely used in cancer treatment, has gained strong recognition for its effectiveness in managing various forms of cancer, including lung cancer and urothelial carcinoma. The increasing...